187 related articles for article (PubMed ID: 31387095)
1. Outcome Predictors of SD-OCT-Driven Intravitreal Ranibizumab in Choroidal Neovascularization due to Myopia.
Guichard MM; Peters G; Tuerksever C; Pruente C; Hatz K
Ophthalmologica; 2020; 243(2):154-162. PubMed ID: 31387095
[TBL] [Abstract][Full Text] [Related]
2. HOW VITREOMACULAR INTERFACE MODIFIES THE EFFICACY OF ANTI-VEGF THERAPY FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Iuliano L; Bandello F
Retina; 2018 Jan; 38(1):84-90. PubMed ID: 28098725
[TBL] [Abstract][Full Text] [Related]
3. Microvasculature Changes of Myopic Choroidal Neovascularization and the Predictive Value of Feeder Vessel Disappearance after Ranibizumab Treatment Revealed Using Optical Coherence Tomography Angiography.
Giorno P; Iacono P; Scarinci F; Di Renzo A; Varano M; Parravano M
Ophthalmologica; 2020; 243(4):263-270. PubMed ID: 31838464
[TBL] [Abstract][Full Text] [Related]
4. FACTORS INFLUENCING VISUAL ACUITY IN PATIENTS RECEIVING ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR FOR MYOPIC CHOROIDAL NEOVASCULARIZATION.
Iacono P; Battaglia Parodi M; Selvi F; Parravano MC; Chiaravalloti A; Varano M; Bandello F
Retina; 2017 Oct; 37(10):1931-1941. PubMed ID: 28033235
[TBL] [Abstract][Full Text] [Related]
5. Vascular endothelial growth factor inhibitors for predominantly Caucasian myopic choroidal neovascularization: 2-year treatment outcomes in clinical practice: data from the Fight Retinal Blindness! Registry.
Gabrielle PH; Nguyen V; Creuzot-Garcher C; Miguel L; Alforja S; Sararols L; Casaroli-Marano RP; Zarranz-Ventura J; Gillies M; Arnold J; Barthelmes D
Acta Ophthalmol; 2022 Feb; 100(1):e288-e296. PubMed ID: 33960115
[TBL] [Abstract][Full Text] [Related]
6. Nine-Year Outcome of Ranibizumab Monotherapy for Choroidal Neovascularization Secondary to Pathologic Myopia.
Pastore MR; Capuano V; Bruyère E; Miere A; Corbelli E; Querques L; Tognetto D; Bandello F; Querques G; Souied EH
Ophthalmologica; 2018; 239(2-3):133-142. PubMed ID: 29268267
[TBL] [Abstract][Full Text] [Related]
7. Long-term follow-up of choroidal neovascularization in pathological myopia treated with intravitreal ranibizumab.
Ladaique M; Dirani A; Ambresin A
Klin Monbl Augenheilkd; 2015 Apr; 232(4):542-7. PubMed ID: 25902117
[TBL] [Abstract][Full Text] [Related]
8. Optical coherence tomography angiography in myopic choroidal neovascularization after intravitreal ranibizumab.
Cennamo G; Amoroso F; Schiemer S; Velotti N; Alfieri M; de Crecchio G
Eur J Ophthalmol; 2019 Mar; 29(2):239-243. PubMed ID: 29991290
[TBL] [Abstract][Full Text] [Related]
9. Vascular remodeling of choroidal neovascularization in older myopic patients treated with ranibizumab.
Cohen SY; Tabary S; El Ameen A; Mrejen S; Quentel G; Giocanti-Auregan A
Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):485-493. PubMed ID: 30535969
[TBL] [Abstract][Full Text] [Related]
10. Fluorescein Leakage and Optical Coherence Tomography Features of Choroidal Neovascularization Secondary to Pathologic Myopia.
Battaglia Parodi M; Iacono P; Romano F; Bandello F
Invest Ophthalmol Vis Sci; 2018 Jun; 59(7):3175-3180. PubMed ID: 30025121
[TBL] [Abstract][Full Text] [Related]
11. LONG-TERM OUTCOMES OF RANIBIZUMAB TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION IN EAST-ASIAN PATIENTS FROM THE RADIANCE STUDY.
Tan NW; Ohno-Matsui K; Koh HJ; Nagai Y; Pedros M; Freitas RL; Macfadden W; Lai TY
Retina; 2018 Nov; 38(11):2228-2238. PubMed ID: 28961671
[TBL] [Abstract][Full Text] [Related]
12. Retinal pigmental epithelium elevation and external limiting membrane interruption in myopic choroidal neovascularization: correlation with activity.
Ding X; Zhan Z; Sun L; Yang Y; Li S; Zhang A; Luo X; Lu L
Graefes Arch Clin Exp Ophthalmol; 2018 Oct; 256(10):1831-1837. PubMed ID: 29982899
[TBL] [Abstract][Full Text] [Related]
13. FIVE-YEAR OUTCOMES OF INTRAVITREAL INJECTION OF RANIBIZUMAB FOR THE TREATMENT OF MYOPIC CHOROIDAL NEOVASCULARIZATION.
Wu TT; Kung YH
Retina; 2017 Nov; 37(11):2056-2061. PubMed ID: 28590318
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcomes of the intravitreal injection of ranibizumab for the treatment of choroidal neovascularization secondary to pathologic myopia.
Wasiluk E; Wojnar M; Obuchowska I; Mariak Z
Int Ophthalmol; 2020 Apr; 40(4):833-839. PubMed ID: 31788714
[TBL] [Abstract][Full Text] [Related]
15. Two different initial treatment regimens of ranibizumab in myopic choroidal neovascularization: 12-month results from a randomized controlled study.
Li S; Ding X; Sun L; Zhao X; Zhang A; Lyu C; Liu B; Zhang J; Jin C; Lu L
Clin Exp Ophthalmol; 2019 Mar; 47(2):250-258. PubMed ID: 30345611
[TBL] [Abstract][Full Text] [Related]
16. Effect of intravitreal injection of aflibercept or ranibizumab on chorioretinal atrophy in myopic choroidal neovascularization.
Sayanagi K; Uematsu S; Hara C; Wakabayashi T; Fukushima Y; Sato S; Ikuno Y; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2019 Apr; 257(4):749-757. PubMed ID: 30643966
[TBL] [Abstract][Full Text] [Related]
17. RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia.
Wolf S; Balciuniene VJ; Laganovska G; Menchini U; Ohno-Matsui K; Sharma T; Wong TY; Silva R; Pilz S; Gekkieva M;
Ophthalmology; 2014 Mar; 121(3):682-92.e2. PubMed ID: 24326106
[TBL] [Abstract][Full Text] [Related]
18. Intravitreal ranibizumab (Lucentis) for the treatment of myopic choroidal neovascularization.
Konstantinidis L; Mantel I; Pournaras JA; Zografos L; Ambresin A
Graefes Arch Clin Exp Ophthalmol; 2009 Mar; 247(3):311-8. PubMed ID: 19043731
[TBL] [Abstract][Full Text] [Related]
19. Is ellipsoid zone integrity essential for visual recovery in myopic neovascularization after anti-VEGF therapy?
Milani P; Pellegrini M; Massacesi A; Moschini S; Setaccioli M; Soranna D; Zambon A; Bottoni F; Bergamini F
Graefes Arch Clin Exp Ophthalmol; 2017 Sep; 255(9):1713-1720. PubMed ID: 28667483
[TBL] [Abstract][Full Text] [Related]
20. Intravitreal ranibizumab for the treatment of choroidal neovascularizations associated with pathologic myopia: a prospective study.
Pasyechnikova NV; Naumenko VO; Korol AR; Zadorozhnyy OS; Kustryn TB; Henrich PB
Ophthalmologica; 2015; 233(1):2-7. PubMed ID: 25501802
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
